Novo Holdings, Vivo lead a record $200M raise for a Singapore-based tools player with plans for a Boston hub, new deals
Close to a year after putting a foot down in Singapore, Novo Holdings has spotted an Asia-based player worth betting a big chunk of its “patient capital” on.
The Danish group is co-leading a $200 million Series A for Esco Lifesciences Group — setting a new record for life sciences tools companies in the region, according to the investor, and funding a sprint toward “Esco 3.0,” where cell and gene therapy process development and manufacturing will loom large.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.